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Introduction
Deletion of the long arm of chromosome 5, del(5q), is the most frequent genomic loss in myeloid diseases. 1 Two distinct common deleted regions (CDR) were identified in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Del(5q), as the sole cytogenetic abnormality, occurs in 10-15% of MDS and is known as "the 5q-syndrome". 1 It is characterized by a 1.5Mb CDR (5q32-q33) where the putative oncosuppressor RPS14 is mapped. 2 Del(5q) associated with other cytogenetic changes, often within a complex karyotype, is prevalent in AML and in high-risk MDS. 3 Here it is characterized by a ~1Mb CDR (5q31) and haploinsufficiency of the oncosuppressor EGR1. 4 Conversely, del(5q) has been rarely reported in B-and T-acute lymphoblastic leukemia (ALL). [5] [6] [7] [8] T-lineage ALL (T-ALL), a heterogeneous group of leukemias, is characterized by co-occurrence of multiple genetic lesions. 9 Interestingly, cooperative genetic defects have been described in T-ALL suggesting that perturbation of specific cell processes are needed for the development of overt leukemia. 10, 11 Translocations causing TAL/LMO, TLX1, TLX3, MYB, MEF2C, NKX2-1/2, or HOXA over-expression define distinct gene expression signatures and are known as "type A" abnormalities. 6, [12] [13] [14] These rearrangements co-occur with multiple mutations and imbalances, named "type B"
abnormalities, which activate oncogenic signalling cascades, including the JAK/STAT, PI3K/AKT, and RAS/MEK/ERK. The most prevalent type B abnormalities are loss-offunction mutations and genomic losses, indicating that tumor suppressor genes, such as
CDKN2A/B, PHF6, LEF1, PTEN, WT1, ETV6
, and PTPN2, play pivotal roles in the initiation of T-ALL.
9,15
To provide insights into the prevalence and specific features of del(5q), in T-ALL, we screened a series of 200 T-ALL cases by fluorescence in situ hybridization (FISH). We found 2 distinct types of recurrent 5q deletions: interstitial (I-5q) and terminal (T-5q). I-5q was identified in 2.5% of cases with a genomic profile closely resembling immature/early T-cell precursor (ETP) ALL. These findings indicates that I-5q is a recurrent cytogenetic event in T-ALL with early differentiation arrest of blasts. T-5q, identified in 9% of cases, clustered within the HOXA category and was characterized by a high incidence of abnormalities involving the CCR4-NOT complex and its closely related transcription factor BTG1. These observations indicate that HOXA over-expression, haplo-insufficiency of genes at T-5q, and deregulation of the CCR4-NOT complex are characteristic of this leukemia subgroup.
Methods
We investigated the incidence of del(5q) in a cohort of 66 adult (≥18 years) and 134 pediatric T-ALL patients from the Italian (GIMEMA LAL-0496 and LAL-0904 and AIEOP Table 1 , Supplementary Information). 10, 16, 17 All patients or their parents/guardians gave informed consent for sample collection and molecular analyses, in agreement with the Declaration of Helsinki. The study was approved by the local bio-ethical committee (research project 2014-025). Table 2) . 10, 16, 17 Deletions of 5q were detected by FISH with LSI EGR1/D5S23, D5S721 Dual Colour probe, RP11-182E4/RP11-453D13 and CTB-31E20/RP11-266N12 for rearrangements of TLX3, RP11-117L6 for NPM1 abnormalities, and RP1-240G13 for deletions of the subtelomeric 5q region. Cases with del(5q) were further characterized with clones for 5p13-qter (Supplementary Table 3 
LLA-2000) and UK clinical trials (MRC, ALL2003 and ALL97) (Supplementary

Combined interphase fluorescence in situ hybridization (CI-FISH) identified T-ALL associated genomic rearrangements which classified cases into defined subgroups (Supplementary
Results and Discussion
Incidence and distribution of del(5q) in T-ALL FISH and SNPa revealed 2 types of recurrent del(5q) in 23/200 T-ALL patients: I-5q (5 cases) ( Table 1) and T-5q (18 cases) ( Table 2 ). In 11/18 cases with T-5q, the deletion was very large and included the common deleted region (CDR) of I-5q cases ( Figure 1A) .
Overall, del(5q) was mainly associated with the HOXA category (16/23; 69,5% Table 4 ).
Deletions of 5q define two independent subgroups of T-ALL
We have data to show that I-5q and T-5q are cytogenetic markers of two T-ALL subgroups of different age and gender distribution and distinct genomic backgrounds.
Interstitial 5q T-ALL
I-5q was detected in 5 patients (2.5%) ( Figure 1) . I-5q T-ALL showed a higher incidence of genomic losses than T-ALL without del(5q) (mean 9,5, [range 1-22] vs 3,1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] ) which, however, did not reach statistical significance likely due to the small sample size (Supplementary Table 4 ). They were significantly associated with WT1 deletions (n=2) (chi-square, p=0.002) and del(6q) (n=3) (chi-square, p=0.002); these del(6q) shared a CDR at band 6q21, encompassing the putative onco-suppressor genes SEC63 and Table 5 ). 7, 19 All I-5q had a CDR at band 5q31 ( Figure 1A) , encompassing the 1Mb CDR of high risk MDS/AML del(5q). 3, 4, 20 When we compared I-5q positive cases with T-5q and T-ALL without del(5q), we found that the expression level of IRF1, EGR1, CTNNA1, HNRNPAO, TIFAB, and CXXC5, which are known putative onco-suppressors in in vitro and/or in vivo models 20-24 mapping within the CDR, did not differ between the three groups; while the presence of I-5q was associated with significant down-regulation of NR3C1 and TCF7
FOXO3 (Supplementary
genes (Figure 1B, Supplementary Information and Supplementary Figures 2 and 3).
NR3C1 belongs to the nuclear hormone receptor super-family that includes the mineralcorticoid and estrogens receptors. Once NR3C1 binds to steroid hormones, it acts as a direct transcriptional regulator. 25 NR3C1 deletion has been associated with relapse in pediatric and adult B-cell ALL and predicted corticosteroid resistance in T-ALL, thus influencing response to treatment. 26, 27 TCF7 is an essential transcriptional regulator of T-cell specification, commitment, and lineage determination. 28 In mouse models, Tcf7
-/-induced a T-cell malignancy that was similar to human ETP-ALL as 117 deregulated genes were common to both. 29 In vivo studies suggested that TCF7 haplo-insufficiency rendered pre-malignant thymocytes susceptible to later lesions that subsequently transformed them into leukemic blasts. In fact, low Tcf7 expression predisposed murine thymocytes to acquire Notch1 activating mutations which were invariably found in Tcf7 -/-lymphomas. 29, 30 Interestingly, NOTCH1 mutations were present in 4/5 cases of T-ALL with I-5q. Together these data suggest strong similarities between mouse Tcf7 -/-T-cell malignancies and human T-ALL with I-5q assigning a role to TCF7 haplo-insufficiency in this leukemia subgroup.
Finally, among HOXA-positive T-ALL, 10/12 cases with immature/ETP or early phenotype lost the I-5q CDR (Supplementary Table 6 and Figure 1C ). Among them 5 cases had the typical features of the high risk subgroup recently named HOXA-positive ETP ALL. 31, 32 As far as we know, loss of genes at the I-5q CDR is the first recurrent cytogenetic change so far described in this subgroup.
Terminal 5q T-ALL
T-5q T-ALL was detected in 18 patients (9%), who were mainly adults (chi-square, p=0.010) but there was no association with gender (12 males; 6 females), stage of blast differentiation (7 pre-T, 5 cortical, 2 ETP, 1 mature, and 3 undefined), or white blood cell count ( 
33-35
Although T-5q deletions varied greatly in size, they all had a common 1.4Mb CDR (chr5:179257527-180719789, GRCh37) telomeric of SQSTM1 ( Figure 1A) . The T-5q CDR In our study, all I-5q T-ALL were characterized by early differentiation arrest of leukemic blasts with expression of at least one stem cell/myeloid antigen ( Table 1) . In fact patients nos. 2 and 5 satisfied all diagnostic criteria for ETP-ALL. 36 RB1/13q14 deletions cooccurred in 2/5 cases. A critical analysis of previous studies showed that del(5q) has been found in immature/ETP ALL. 6, 34 Indeed, del(5q) together with del(13q) were the two cytogenetic changes most frequently associated with immature/ETP ALL as they were both detected in 23% of cases (4/17), and co-occurred in 11% (2/17). 6, 36 Additional evidence that I-5q T-ALL are closely related to the immature/ETP subtype of T-ALL came from identification of PHF6, JAK3, JAK1, DNM2, WT1, ETV6, and/or RUNX1 mutations and lack of CDKN2AB deletion/mutation in all analysed cases.
37,40,41
It is noteworthy that in addition to TCF7, also TDRKH, PCGF5, HDAC4, and MTA3 were significantly down-regulated in I-5q T-ALL so that our I-5q patients carried 5/10 of the most differentially expressed (down-regulated) genes seen in human ETP-ALL (Supplementary Table 7 Terminal 5q is a HOXA positive cytogenetic subgroup T-5q was found in 27% of patients belonging to the HOXA group (13/48 cases) (chisquare; p<0.001) in which it behaved as type B event ( Table 2) . Supervised GEP analysis Within the T-5q CDR we observed down-regulation of TRIM41, ZFP62, MAPK9, MGAT1, and interestingly, CNOT6. This is the first report of CNOT6 involvement in human cancer and its down-regulation is consistent with putative onco-suppressor gene as indicated by in vitro data. 46 Besides CNOT6 down-regulation, our T-5q T-ALL were associated with a high rate of CNOT3 mutations (18%). Notably, CNOT3 loss-of-function mutations were found in ~7% of adult T-ALL but no specific association with any major molecular subgroups has been reported. 47 Both CNOT6 and CNOT3 encode for members of the CCR4-NOT complex, which consists of two major modules: the deadenylase module composed of two subunits with deadenylation enzymatic activity (CNOT6 or CNOT6L and CNOT7 or CNOT8) and the NOT module (CNOT1, CNOT2, and CNOT3). The CCR4-NOT complex is involved in chromatin modification, cellular response to DNA-damage, transcription elongation, RNA export, nuclear RNA surveillance, and miRNA-mediated deadenylation of mRNA. [48] [49] [50] Although, CCR4-NOT involvement in human tumours has been rarely reported, a recurrent hotspot P131L mutation of RQCD1 (formerly known as CNOT9) has been recently identified in ~4% of cutaneous melanoma. 51 Our findings of a high rate of deletion/loss-of-function mutations and down-regulation of members of the CCR4-NOT complex as well as low expression of BTG1, a directly interacting adaptor protein of CCR4-NOT, suggest that this complex plays a role in the subset of HOXA positive T-ALL with T-5q.
In conclusion, the present study has identified distinct recurrent 5q deletions in T-ALL, corresponding to different genomic landscapes and defining 2 cytogenetic subgroups. I-5q
identified a subgroup of immature T-ALL, found predominantly in females, with an ETP-like genetic profile and poor response to current treatments. T-5q designated a subgroup of HOXA-positive T-ALL, mainly found in adults and associated with a high rate of CCR4-NOT complex abnormalities. In I-5q, two putative onco-suppressors NR3C1 and TCF7, mapping to the 5q31 CDR, were down-regulated. In T-5q CNOT6, a member of the CCR4-NOT complex, mapping to the 5q35 CDR, was significantly down-regulated. Due to the heterogeneity of treatment and age of our 18 patients, the clinical impact of T-5q could not be established, while the unresponsive T-ALL with I-5q should be considered for new experimental therapies. No., patient number; S, sex; A, age; F, female; M, male; CI-FISH, combined interphase fluorescence in situ hybridization (the percentage of cells with abnormal CI-FISH is indicated between brackets); CNV, copy number variation (detected by SNPa); n.a., not available; nl, normal; del, deletion; †, dead. Patient no.3 was studied by haloplex; nos. 12, 16, and 17 by RNAseq; no. 5 was not studied for gene mutations. Patients nos. 4 and 15 were wild type for hotspot mutations of NOTCH1, FBXW7, FLT3, TP53, CNOT3, K/NRAS. Gene expression profiling was performed in patients nos. 4, 6, 12, 15-18. In patient no.8 the T-5q was detected 13 months after diagnosis, while the patient was still doing treatment.
Legends to the figure Figure 1 . panel A) patient's numbers refer to Table 1 for cases with I-5q, and to Table 2 for cases with T-5q. Black boxes indicate monoallelic deletion; grey boxes, diploidy; white boxes, not tested; gain, presence of 3 copies; panel B) TCF7 and NR3C1 expression in 2
T-ALL with I-5q vs control (7 cases without del(5q) and 3 cases with T-5q); panel C)
Distribution of terminal CDR (tCDR) (black) (3 cases) and interstitial CDR (iCDR) (grey) (3 cases with I-5q and 9 cases with large T-5q including the I-5q CDR) within the HOXAcategory: all 5 cases with an immature/ETP phenotype as well as 5/7 early T-ALL had I-5q or large T-5q including the iCDR; panel D) Expression of CD34, MEF2C, and LMO2 in 2 cases with I-5q vs 10 controls (7 cases without del(5q) and 3 cases with T-5q); panel E)
Supervised GEP analysis of 4 HOXA positive cases with T-5q (t) and 6 without (n), identified 327 differentially expressed genes.
Materials and methods
Patients. The cohort comprised of 149 males and 51 females (ratio: 2.9); 134 were children (18 years) and 66 were adults (>18 years). Blast stage differentiation arrest could be precisely defined in 101 cases for which a complete panel of antibodies was tested: 6 early T-cell precursor (ETP-ALL), 9 mature, 42 pre-T, and 44 cortical. Molecularcytogenetic analysis classified 160 cases (80%) into one of the main genetic groups (Supplementary Table 2 ) and identified concurrent genomic abnormalities (Supplementary Table 1 ).
1-3
Combined Interphase Fluorescence in situ Hybridization (CI-FISH). CI-FISH was done with 96 genomic clones to investigate 51 genes/loci that are putatively involved in T-ALL (Supplementary Table 8 ). Clonal analysis of FISH abnormalities was carried out on 150 interphase nuclei. Differences exceeding 20% between different abnormalities, in the same sample, was the cut-off to discriminate the main clone from sub-clones. To determine the clonal origin of the rearrangements dual colour FISH was performed. In cases with karyotypic evidence of del(5q), loss of EGR1 and/or TLX3, the 5q deleted region was characterized using genomic probes for 5p13-qter (Supplementary Table 3 ).
In 5 cases, with terminal 5q deletions (T-5q) and abnormal metaphases, repetitive telomeric sequences were studied using Telomere PNA FISH probe (DAKO, an Agilent
Technologies Company, Milano, Italy).In patient no.8 (Table 2 ), the T-5q was detected during disease progression (13 months after diagnosis, the first time he was referred to our Mutational analysis. RNASeq analysis was performed on 2 cases with interstitial 5q-(I5q) (patient nos. 2 and 3, Table 1 ), in 3 with T-5q (patient nos. 12, 16, and 17, 
7-12
Gene expression Profile (GEP). Gene expression profiling was carried out using the HGU133 Plus 2.0 gene (Affymetrix, CA) following manufacturer's instructions.
Unsupervised clustering was performed as previously described: 13 and FOXO3, at band 6q21. Table 2) . T-5q were found in 18 cases (9%), were predominant in adults (11/18) (chi-square, p=0.010) but did not show a gender distribution if compared with T-ALL without del(5q). T-5q was cryptic in 16/18 (89%) cases. Deletions varied widely in size, but a 1.4Mb CDR, telomeric to SQSTM1, was identified as the minimally common deleted region (seeT-5q in patient no. 15). In the 5 cases investigated, the repetitive telomeric sequences remained at T-5q. CI-FISH detected 1-6 additional abnormalities in all 18 cases, classifying 13 into the HOXA category and 2 into the TLX3. In both TLX3-positive cases (nos. 17 and 18 of Table 2 ) the T-5q flanked the telomeric end of TLX3 (loss of RP11-117L6, flanking the 3'TLX3). BCL11B break-apart and BCL11B-TLX3 double colour double fusion assays identified the rearrangement in case no.18. Gene expression analysis showed that the TLX3 expression level was at least 11-fold the median value in both cases (Supplementary Figure 4) . The remainder 3 cases of T-5q T-ALL were unclassified. T-5q was significantly associated with NF1 deletion (16.7% of cases) (Chisquare, p=0.002) and del(6q) (6/18 cases, 33%) (Chi-square, p=0.02). Del(6q) was heterogeneous in size but all shared the loss of bands 6q14-q15 (see also SNPa data).
T-5q (
A differential gene expression analysis was performed with the R-package DESeq2, which calculates for each gene the fold change, the p-value and the adjusted p-value. In this analysis the expression of all genes was compared between the cases with 5q deletions and the cases without these deletions (I-5q and T-5q separately). For T-5q, 110 genes were identified to be up-regulated, while only 48 genes were down-regulated (in both cases p<0.005). In the I-5q cases, 465 genes were down-regulated and 159 genes were up-regulated (p<0.005). Moreover, we investigated the expression levels of a number of interesting genes. In the I-5q samples, we observed a clear down-regulation of TCF7 and
NR3C1oncosuppressors located within the CDRs (Figure 1B) . In addition, we observed a slight down-regulation of WT1, while JAK3 and NOTCH1 were up-regulated. In the T-5q
cases, we perceived a slight down-regulation of CNOT3 and of CNOT6, as well as a Table 2 ) and 2 I-5q T-ALL (patients nos. 2 and 3 of Table 1 ).
